MGNX Shares Outstanding History



Below is a table of the MGNX shares outstanding history going back to 10/10/2013:

Date MGNX Shares Outstanding
10/10/201323.02M
10/31/201325.02M
2/28/201427.47M
4/30/201427.62M
7/31/201427.74M
10/31/201427.79M
2/27/201529.97M
4/30/201530.05M
7/31/201534.20M
10/30/201534.31M
2/22/201634.53M
4/29/201634.55M
7/29/201634.73M
10/31/201634.84M
2/24/201734.97M
4/28/201735.01M
7/31/201736.80M
11/3/201736.82M
2/23/201836.92M
5/4/201842.20M
8/3/201842.24M
11/2/201842.26M
2/22/201948.78M
4/26/201948.81M
7/26/201948.89M
7/22/2019116.91M
11/1/201948.92M
2/21/202048.98M
5/1/202049.14M
7/24/202054.12M
10/30/202056.20M
2/22/202156.26M
4/26/202160.04M
7/26/202161.11M
10/29/202161.26M
2/22/202261.32M
4/29/202261.33M
8/3/202261.46M
10/31/202261.48M
2/28/202361.84M
5/5/202361.84M
8/4/202361.95M
11/3/202362.03M
3/1/202462.43M

Also see: MGNX Market Cap History
MGNX YTD Return
MGNX Historical Shares Outstanding:
+10.07% CAGR
MGNX Historical Shares Outstanding: +10.07% CAGR

Mouse over chart for data details
10/10/2013 ...3/1/2024
MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is vobramitamab duocarmazine, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia. We show 44 historical shares outstanding datapoints in our coverage of MGNX's shares outstanding history.

Understanding the changing numbers of MGNX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like MGNX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching MGNX by allowing them to research MGNX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree MGNX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
MacroGenics (MGNX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

MGRM Shares Outstanding History
MGTA Shares Outstanding History
MIGI Shares Outstanding History
MIRA Shares Outstanding History
MIRM Shares Outstanding History
MIRO Shares Outstanding History
MLAB Shares Outstanding History
MLND Shares Outstanding History
MLNT Shares Outstanding History
MLYS Shares Outstanding History
More Healthcare companies »

 

MGNX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.